Aesthetic Recall & Safety Alert Watch

AbbVie filed multiple material events (8-K filings) in 2026 related to Allergan Aesthetics operations, signaling either product-related issues, regulatory developments, or business restructuring. While the specific details of these filings require direct SEC review, material events typically indicate:

• Product safety or efficacy findings requiring disclosure
• Regulatory warning letters or compliance actions
• Supply chain disruptions
• Significant litigation or settlements

Action for practices: Check the SEC EDGAR database directly (search "AbbVie 8-K 2026") and cross-reference with your Allergan Aesthetics sales rep. Request written clarification on whether any Botox, Juvéderm, or Voluma SKUs are affected. Do not rely on email chatter; get it in writing. If you hold inventory of any Allergan product, verify batch numbers against any recall notices issued through the FDA's Enforcement Reports page.

Skinvive (hyaluronic acid filler for skin quality/hydration) received FDA approval for neck lines and appearance improvement in 2026. This is a new indication and new product category—not a traditional volumizer. Key distinctions:

• Skinvive is a superficial dermal hydrator, not a structural filler
• Cleared for horizontal neck lines and neck appearance, not midface or lip volume
• Different injection depth and technique than Juvéderm Ultra or Voluma
• Pricing and rebate structure (Alle program) may differ from traditional fillers

Action for practices: Verify your Allergan rep has provided updated training on injection depth, needle gauge, and patient selection. Do not use Skinvive off-label for lips or cheeks without documented informed consent. Confirm whether your Alle rebate tier includes Skinvive or if it's a separate SKU code. Stock only what you can realistically inject; superficial fillers have shorter shelf life post-opening.

Galderma received FDA approval for Restylane Contour for temple hollowing correction in 2026. This represents a new indication for an existing product and expands the addressable patient population. Temple volume loss is increasingly recognized as a driver of facial aging, especially in post-weight-loss and GLP-1 patients.

• Restylane Contour is a cohesive, moldable filler designed for structural support
• Temple injection requires precise anatomical knowledge (superficial temporal artery, frontal branch of facial nerve)
• Different technique than cheek or lip injection

Action for practices: Request Galderma training on temple anatomy and injection technique if you plan to offer this. Verify your Aspire rebate program includes this indication. Temple injections carry higher complication risk (hematoma, nerve injury); ensure your informed consent explicitly addresses temple-specific risks. Consider this a premium service with appropriate pricing.

RHA Dynamic Volume received FDA clearance for midface augmentation and age-related volume loss in 2026. RHA (Resilient Hyaluronic Acid) is a dynamic, non-cross-linked HA filler with different rheology than traditional Restylane or Juvéderm products:

• Lower G' (storage modulus) = more movement and natural feel in dynamic zones
• Designed for areas requiring facial expression (smile lines, midface)
• Different injection technique than rigid fillers
• Pricing and rebate structure (Aspire) differ from Restylane Lyft or Voluma

Action for practices: This is a new product category requiring new training. Do not assume your existing HA injection skills transfer directly. Request hands-on training from Galderma. Verify Aspire rebate eligibility and per-syringe cost. Stock conservatively until you master technique; dynamic fillers require different patient counseling (expect more movement, less definition than traditional fillers).

Industry consensus now confirms that GLP-1 agonists (semaglutide, tirzepatide, others) cause rapid, significant facial fat loss—colloquially "semaglutide face." This is not a recall, but a clinical reality reshaping practice demand:

• Facial fat loss occurs within weeks to months of GLP-1 initiation
• Affects periorbital, malar, and temporal regions disproportionately
• Creates new patient cohort seeking volume restoration (biostimulators, traditional fillers)
• Patients may not disclose GLP-1 use; ask directly

Action for practices: Screen all new volume-loss patients for GLP-1 use. Adjust filler selection and volume accordingly—GLP-1 patients often need more aggressive volumization than age-matched controls. Consider stocking biostimulators (Sculptra, Radiesse) for this cohort; they provide longer-lasting results than HA fillers and address collagen loss, not just volume. Educate patients that filler alone may not address the underlying collagen deficit. This is a growth opportunity, not a liability—but requires proactive patient communication.

Allergan Aesthetics received Health Canada approval for Boey (trenibotulinumtoxin E), a rapid-onset, short-duration neuromodulator for glabellar lines. This is not yet FDA-approved in the U.S., but signals a coming competitive product:

• Onset: 24–48 hours (vs. 3–7 days for Botox)
• Duration: ~6 weeks (vs. 12–16 weeks for Botox)
• Different dosing units and diffusion profile than Botox or Dysport
• Likely higher per-unit cost due to shorter duration

Action for practices: Monitor FDA approval timeline (likely 2026–2027). Do not import or use Boey in the U.S. until FDA clearance. If approved, expect Allergan to position it as a premium, rapid-result option for special events or trial patients. Pricing and rebate structure unknown; await official launch details. Existing Botox/Dysport inventory remains unaffected.

InMode Ltd. (NASDAQ: INMD), a major RF microneedling and energy-device manufacturer, received an unsolicited acquisition proposal at $16.20/share in June 2026. While not a safety issue, acquisition uncertainty can disrupt device support, software updates, and parts availability:

• InMode manufactures Morpheus8 (RF microneedling), Lumenis devices (via partnership)
• Acquisition could trigger management changes, R&D delays, or service disruptions
• Existing device warranties and support contracts may be affected

Action for practices: If you own InMode devices (Morpheus8, etc.), verify your service contract terms and parts availability. Contact your InMode rep to confirm post-acquisition support commitments. Do not make new device purchases until acquisition closes and new ownership structure is clear. Monitor InMode's SEC filings for updates; material changes to device support or pricing will be disclosed.

High-profile criminal cases continue to emerge: a Port St. Lucie med spa owner received 45 years for botched cosmetic surgery; unlicensed injection operations are being prosecuted in Arizona and elsewhere. These are not product recalls, but they underscore regulatory risk:

• Unlicensed injectors and unregulated facilities face federal charges
• State medical boards are aggressively pursuing scope-of-practice violations
• Botched outcomes (nerve injury, infection, disfigurement) trigger both civil and criminal liability

Action for practices: Verify that all injectors (MDs, DOs, NPs, PAs, RNs) hold current, active licenses and are operating within state scope-of-practice limits. Maintain written protocols for supervision and delegation. Document informed consent, pre-injection photos, and post-injection follow-up. Carry adequate malpractice insurance with coverage for off-label use. If you operate as an MSO or employ injectors, ensure your corporate structure complies with your state's Corporate Practice of Medicine doctrine.